Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990825 | 0.80 | CYP2A6 (0.39) | CYP2A6ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL12004479 | 0.76 | HCAR2 (0.33) | — | |
| SCHEMBL990826 | 0.75 | — | — | |
| SCHEMBL1832864 | 0.75 | LMNA (0.43) | CYP3A4CYP1A2CYP19A1KDM4ELMNA | |
| SCHEMBL988803 | 0.73 | CYP2A6 (0.53) | CYP2A6ALDH1A1CYP3A4CYP1A2HSP90AA1 | |
| SCHEMBL29419014 | 0.71 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL30473120 | 0.71 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL120088 | 0.71 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL943994 | 0.71 | NISCH (0.39) | CYP1A2HSP90AA1CYP19A1METAP2KDM4E | |
| SCHEMBL15477525 | 0.70 | KMO (0.45) | CYP19A1TP53SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024051766-A1 | MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-03-14 | — | — | WO | claimed |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-05-12 | — | — | US | claimed |
| EP-3932922-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | ShanghaiTech University (CN) | 2022-01-05 | — | — | EP | claimed |
| US-10738028-B2 | Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor | RUDONG RUIEN PHARMACEUTICAL TECHNOLOGY CO. LTD (CN) | 2020-08-11 | — | — | US | claimed |
| US-20190194165-A1 | SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOR | RUDONG RUIEN PHARMACEUTICAL TECHNOLOGY CO. LTD (CN) | 2019-06-27 | — | — | US | claimed |
| EP-3483155-A1 | SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOUR. | Rudong Ruien Pharmaceutical Technology Co., Ltd. (CN) | 2019-05-15 | — | — | EP | claimed |
| WO-2011008788-A1 | FLUORO-SUBSTITUTED COMPOUNDS AS KINASE INHIBITORS AND METHODS OF USE THEREOF | ZHANG DAWEI (US) | 2011-01-20 | — | — | WO | claimed |
| EP-0946528-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998028282-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | claimed |
| WO-2024051766-A1 | MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-03-14 | — | — | WO | disclosed |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-05-12 | — | — | US | disclosed |
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | STANDARD LLC (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3932922-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | ShanghaiTech University (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-10738028-B2 | Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor | RUDONG RUIEN PHARMACEUTICAL TECHNOLOGY CO. LTD (CN) | 2020-08-11 | — | — | US | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| EP-1427415-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-06-16 | — | — | EP | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738028-B2 | Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor | PDF, HSPE1, ERAL1 | CYP2A6 3026/4885ALDH1A1 1847/4885CYP3A4 2592/4885 |
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | MEF2D, MYLK2, TNNT2 | CYP2A6 3964/4885ALDH1A1 4009/4885CYP3A4 4160/4885 |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | GLS, SQOR, GCDH | CYP2A6 1769/4885ALDH1A1 958/4885CYP3A4 1182/4885 |
| US-20190194165-A1 | SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOR | PDF, HSPE1, ATP5PB | CYP2A6 3226/4885ALDH1A1 2044/4885CYP3A4 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.